Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 6/20 | 1.00 |
| ▸ | PDGFRA | P16234 | 5/20 | 0.66 |
| ▸ | FLT3 | P36888 | 2/20 | 0.65 |
| ▸ | PDGFRB | P09619 | 8/20 | 0.59 |
| ▸ | KDR | P35968 | 1/20 | 0.59 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.52 |
| ▸ | CLK1 | P49759 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15384140 | 0.88 | KIT (0.79) | KITPDGFRAFLT3PDGFRBKDR | |
| SCHEMBL13771452 | 0.86 | KIT (0.76) | KITPDGFRAFLT3PDGFRBPIK3CA | |
| Amuvatinib SCHEMBL29351463 | 0.80 | KIT (1.00) | KITPDGFRAFLT3PDGFRBKDR | |
| Amuvatinib SCHEMBL29431554 | 0.80 | KIT (1.00) | KITPDGFRAFLT3PDGFRBKDR | |
| Amuvatinib SCHEMBL93976 | 0.80 | KIT (1.00) | KITPDGFRAFLT3PDGFRBKDR | |
| Amuvatinib SCHEMBL1686091 | 0.79 | KIT (1.00) | KITPDGFRAFLT3PDGFRBKDR | |
| Amuvatinib SCHEMBL29883318 | 0.79 | KIT (1.00) | KITPDGFRAFLT3PDGFRBKDR | |
| SCHEMBL1028115 | 0.78 | KIT (0.66) | KITPDGFRAFLT3PDGFRBKDR | |
| SCHEMBL3868451 | 0.77 | PIK3CA (0.67) | KITKDRPIK3CACLK1ALDH1A1 | |
| SCHEMBL1028117 | 0.75 | PDGFRB (0.61) | KITPDGFRAFLT3PDGFRBKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8999988-B2 | Protein kinase inhibitors | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2015-04-07 | — | — | US | disclosed |
| US-8999988-B2 | Protein kinase inhibitors | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2015-04-07 | — | — | US | disclosed |
| US-20130302303-A1 | PROTEIN KINASE INHIBITORS | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2013-11-14 | — | — | US | disclosed |
| US-20130302303-A1 | PROTEIN KINASE INHIBITORS | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2013-11-14 | — | — | US | disclosed |
| US-8552018-B2 | Substituted tricyclic compounds as protein kinase inhibitors | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2013-10-08 | — | — | US | disclosed |
| US-20110212929-A1 | Protein Kinase Inhibitors | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2011-09-01 | — | — | US | disclosed |
| US-20110212929-A1 | Protein Kinase Inhibitors | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2011-09-01 | — | — | US | disclosed |
| EP-1678166-B1 | PROTEIN KINASE INHIBITORS | UNIV ARIZONA (US) | 2009-07-29 | — | — | EP | disclosed |
| US-20090143399-A1 | Protein Kinase Inhibitors | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2009-06-04 | — | — | US | disclosed |
| US-20090143399-A1 | Protein Kinase Inhibitors | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2009-06-04 | — | — | US | disclosed |
| US-20080051414-A1 | Protein Kinase Inhibitors | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2008-02-28 | — | — | US | disclosed |
| US-20080051414-A1 | Protein Kinase Inhibitors | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2008-02-28 | — | — | US | disclosed |
| US-7335662-B2 | Substituted tricyclic compounds as protein kinase inhibitors | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2008-02-26 | — | — | US | disclosed |
| US-7335662-B2 | Substituted tricyclic compounds as protein kinase inhibitors | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2008-02-26 | — | — | US | disclosed |
| US-7326712-B2 | Substituted tricyclic compounds as protein kinase inhibitors | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2008-02-05 | — | — | US | disclosed |
| US-7326712-B2 | Substituted tricyclic compounds as protein kinase inhibitors | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2008-02-05 | — | — | US | disclosed |
| US-7326713-B2 | Substituted tricyclic compound as protein kinase inhibitors | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2008-02-05 | — | — | US | disclosed |
| US-7326713-B2 | Substituted tricyclic compound as protein kinase inhibitors | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2008-02-05 | — | — | US | disclosed |
| US-7312226-B2 | Substituted tricyclic compounds as protein kinase inhibitors | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2007-12-25 | — | — | US | disclosed |
| US-7312226-B2 | Substituted tricyclic compounds as protein kinase inhibitors | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2007-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130302303-A1 | PROTEIN KINASE INHIBITORS | CDK2, MAP3K1, MAP3K2 | KIT 1558/4885PDGFRA 2162/4885FLT3 228/4885 |
| US-20110212929-A1 | Protein Kinase Inhibitors | CDK2, MAP3K1, MAP3K2 | KIT 1558/4885PDGFRA 2162/4885FLT3 228/4885 |
| US-20080051414-A1 | Protein Kinase Inhibitors | CDK2, MAP3K1, MAP3K2 | KIT 1558/4885PDGFRA 2162/4885FLT3 228/4885 |
| US-20090143399-A1 | Protein Kinase Inhibitors | CDK2, MAP3K1, MAP3K2 | KIT 1558/4885PDGFRA 2162/4885FLT3 228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.